SW

Steve Weinstein

Venture Investor, CEO and Life Science Executive

Greater Boston

Invests in

Stages:

  • Min Investment:

    $5,000.00
  • Max Investment:

    $50,000.00
  • Target Investment:

    $25,000.00

Work Experience

  • Senior Advisor

    2024

    UPMC Enterprises is the innovation, commercialization, and venture capital arm of UPMC.

  • Innovation Consultant

    2024

  • Expert-in-Residence (XIR)

    2025

    Advise ARPA-H on how to translate their programs from bench to bedside. Advise innovators working on early-stage healthcare technologies.

  • Strategic Advisor

    2019

    Clinical research and commercial translation strategy related to mental health, neuomodulation, addiction, and digital tools in clinical practice.

  • Managing Member

    2018

    Consultant and Advisor to Venture Funds, Venture Funded Start-ups & Academic Medical Centers

  • Product Development Review Council Member

    2018

    Council reviews oncology-focused grants of up to $20M/company.

  • Board Member

    2021

  • CEO

    2021 - 2023

    • Joined as Independent Director. Became Interim CEO to build senior leadership team including CSO, CMO, and Data Science. Developed new R&D and clinical strategy. • Development stage prostate cancer prognostic for monitoring patients with low risk tumors.

  • Board Member

    2021

    Developing an ingestible drug/device which detects and reverses opioid overdose.

2021 - 2024

  • Consultant, Neuroscience Innovation

    2021 - 2024

    • Evaluate technologies and manage projects that transform the treatment of neurological diseases including neuromuscular, precision psychiatry, and drug delivery. • Developed best practices recommendations for corporate innovation.

2019 - 2024

  • Chairman

    2019 - 2024

    • Next generation intravascular cardiology imaging combining DeepOCT™ imaging, near infrared spectroscopy (NIRS), and AI-powered insights to optimize coronary stenting and better inform care.

Latest Articles